Opthea Ltd
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well… Read more
Market Cap & Net Worth: Opthea Ltd (OPT)
Opthea Ltd (NASDAQ:OPT) has a market capitalization of $524.82 Million ($524.82 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10039 globally and #4708 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Opthea Ltd's stock price $3.41 by its total outstanding shares 153906000 (153.91 Million).
Opthea Ltd Market Cap History: 2016 to 2025
Opthea Ltd's market capitalization history from 2016 to 2025. Data shows change from $687.78 Million to $524.82 Million (-4.48% CAGR).
Index Memberships
Opthea Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.02% | #277 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1042 of 3165 |
Weight: Opthea Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Opthea Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Opthea Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4848.68x
Opthea Ltd's market cap is 4848.68 times its annual revenue
1728.56x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $2.48 Billion | $112.50K | -$20.91 Million | 22053.61x | N/A |
| 2020 | $1.73 Billion | $145.90K | -$16.12 Million | 11830.48x | N/A |
| 2021 | $1.16 Billion | $91.98K | -$60.79 Million | 12624.57x | N/A |
| 2022 | $824.94 Million | $125.05K | -$127.99 Million | 6597.01x | N/A |
| 2023 | $454.02 Million | $161.16K | -$211.88 Million | 2817.16x | N/A |
| 2024 | $604.47 Million | $124.67K | -$220.24 Million | 4848.68x | N/A |
Competitor Companies of OPT by Market Capitalization
Companies near Opthea Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Opthea Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Opthea Ltd Historical Marketcap From 2016 to 2025
Between 2016 and today, Opthea Ltd's market cap moved from $687.78 Million to $ 524.82 Million, with a yearly change of -4.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $524.82 Million | -13.18% |
| 2024 | $604.47 Million | +33.14% |
| 2023 | $454.02 Million | -44.96% |
| 2022 | $824.94 Million | -28.96% |
| 2021 | $1.16 Billion | -32.72% |
| 2020 | $1.73 Billion | -30.43% |
| 2019 | $2.48 Billion | +362.16% |
| 2018 | $536.82 Million | -28.90% |
| 2017 | $755.00 Million | +9.77% |
| 2016 | $687.78 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 16th, 2026 the market cap of Opthea Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $524.82 Million USD |
| MoneyControl | $524.82 Million USD |
| MarketWatch | $524.82 Million USD |
| marketcap.company | $524.82 Million USD |
| Reuters | $524.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.